Departments of Pathology.
Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands.
Am J Surg Pathol. 2019 Nov;43(11):1547-1553. doi: 10.1097/PAS.0000000000001339.
Condyloma acuminatum rarely occurs in the urinary bladder and is considered to be a risk factor for squamous cell carcinoma, although there are only a few publications with limited cases. We studied 51 cases of condyloma acuminatum of the urinary bladder from transurethral resections of the urinary bladder of 38 patients from the consult files of one of the authors. Transurethral resections of the urinary bladder were obtained from 25 males with a median age of 73 years (range: 41 to 87 y) and 13 females with a median age of 68 years (range: 30 to 86 y). The follow-up period ranged from 15 months to 20 years (median: 6 y). Bladder lesions were accompanied by urethral lesions in 4 men. Eight patients (8/38; 21.0%) had a history of immunosuppression. Seven patients (7/8; 87.5%) from this group had multiple and/or recurrent condylomas. One patient (1/38; 2.6%) with renal transplantation had 10 separate bladder condylomas over time. One patient (1/38; 2.6%) had extensive anogenital condylomas and anal intraepithelial neoplasia grade 3. One patient (1/8; 12.5%) with renal transplantation presented with a solitary condyloma with synchronous squamous cell carcinoma in situ. Three female patients (3/38; 7.9%) had a history of premalignant vagina/cervix lesions. In total, 17 patients (17/38; 44.7%) had squamous cell carcinoma of the bladder, either invasive or in situ. In all cases, the squamous cell carcinoma (either in situ or invasive) was diagnosed either concurrent with the diagnosis of bladder condyloma or within 1 year of the condyloma diagnosis). In total, 9 of 38 (23.7%) patients had invasive squamous cell carcinoma with or without in situ squamous cell carcinoma. Eight of 38 (21.0%) patients had squamous cell carcinoma in situ only (without a definitive invasive component-in 3 cases invasive squamous cell carcinoma could not be excluded with certainty). In total, 19 patients (19/38; 50%) were positive for either low-risk human papillomavirus (LR-HPV) or high-risk human papillomavirus (HR-HPV) or both (3 were positive for both LR-HPV and HR-HPV, 12 patients for only LR-HPV, and 4 for only HR-HPV). Of the 19 patients that were negative for both LR-HPV and HR-HPV, 9 of 19 (47.4%) patients had associated squamous cell carcinoma. Of the 12 patients with only LR-HPV, 4 (33.3%) had associated squamous cell carcinoma (either invasive or in situ). Of the 7 patients with HR-HPV (with or without LR-HPV), 4 (57.1%) has associated squamous cell carcinoma. In summary, condyloma acuminatum of the urinary bladder shows a strong association with squamous cell carcinoma of the bladder, regardless of the condyloma's HPV in situ hybridization results. Immunosuppression is associated with condylomas of the bladder. It is important to distinguish bladder condylomas from papillary urothelial carcinoma, given their different risks for panurothelial disease and risk of squamous cell carcinoma. Recognition of bladder condylomas histologically is often challenging given their rarity, and that they can be negative for both LR-HPV and HR-HPV. The lack of a history of other anogenital human papillomavirus-related lesions further increases the difficulty in establishing the correct diagnosis.
尖锐湿疣很少发生在膀胱,被认为是鳞状细胞癌的一个危险因素,尽管只有少数几篇病例有限的文献报道。我们研究了 51 例来自作者之一的咨询档案中 38 例患者的经尿道膀胱切除术的膀胱尖锐湿疣。25 例男性经尿道膀胱切除术患者的中位年龄为 73 岁(范围:41 至 87 岁),13 例女性患者的中位年龄为 68 岁(范围:30 至 86 岁)。随访时间从 15 个月到 20 年不等(中位时间:6 年)。膀胱病变伴有尿道病变的有 4 例男性。8 例患者(8/38;21.0%)有免疫抑制病史。该组中有 7 例(7/8;87.5%)患者有多发性和/或复发性尖锐湿疣。1 例(1/38;2.6%)肾移植患者随时间推移出现了 10 个单独的膀胱尖锐湿疣。1 例(1/38;2.6%)患者有广泛的肛门生殖器尖锐湿疣和 3 级肛门上皮内瘤变。1 例(1/8;12.5%)肾移植患者出现孤立性尖锐湿疣,伴有同步原位鳞状细胞癌。3 例女性患者(3/38;7.9%)有阴道/宫颈前病变病史。总共 17 例(17/38;44.7%)患者患有浸润性或原位膀胱癌。在所有病例中,鳞状细胞癌(原位或浸润性)的诊断与膀胱尖锐湿疣同时或在尖锐湿疣诊断后 1 年内做出。总共 9 例(38 例中的 23.7%)患者有浸润性鳞状细胞癌,伴或不伴原位鳞状细胞癌。8 例(38 例中的 21.0%)患者仅为原位鳞状细胞癌(无明确浸润成分-在 3 例中不能确定是否有浸润性鳞状细胞癌)。总共 19 例(38 例中的 19%)患者 HPV 低危型(LR-HPV)或高危型(HR-HPV)或两者均为阳性(3 例同时为 LR-HPV 和 HR-HPV 阳性,12 例仅为 LR-HPV 阳性,4 例仅为 HR-HPV 阳性)。在 LR-HPV 和 HR-HPV 均为阴性的 19 例患者中,9 例(47.4%)患者有相关的鳞状细胞癌。在仅为 LR-HPV 的 12 例患者中,4 例(33.3%)有相关的鳞状细胞癌(浸润性或原位)。在 7 例 HR-HPV 阳性(伴或不伴 LR-HPV)患者中,4 例(57.1%)有相关的鳞状细胞癌。总之,膀胱尖锐湿疣与膀胱癌之间存在很强的关联,无论 HPV 原位杂交结果如何。免疫抑制与膀胱尖锐湿疣有关。重要的是要区分膀胱尖锐湿疣和乳头状尿路上皮癌,因为它们有不同的泛尿路上皮疾病风险和鳞状细胞癌风险。鉴于其罕见性,以及其可能同时为 LR-HPV 和 HR-HPV 阴性,因此在组织学上识别膀胱尖锐湿疣具有挑战性。由于缺乏其他肛门生殖器 HPV 相关病变的病史,进一步增加了正确诊断的难度。